Trial Profile

A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Ubidecarenone (Primary)
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Therapeutic Use
Sponsors Berg Pharma

Most Recent Events

26 Mar 2025 Number of treatment arms are increased from 1 to 2 by the addition of Experimental: BPM31510 monotherapy arm, thus changing the study design from single group assignment to Parallel.
20 Jan 2024 Results presented at the 2024 Gastrointestinal Cancers Symposium
18 Jan 2024 Results presented in BPGbio media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com